

## ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Final analysis of the TITAN study of apalutamide (APA) versus placebo presented at ASCO 2021 in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy demonstrated which of the following outcomes with APA?**
  - Overall survival benefit without a significant negative impact on quality of life
  - Overall survival benefit with a significant negative impact on quality of life
- Of the toxicities listed below, which best describes those that may be experienced by patients who are receiving erdafitinib?**
  - Hypertension, renal impairment and myelosuppression
  - Thrombocytopenia, pneumonitis and cognitive impairment
  - Hyperphosphatemia, ocular and gastrointestinal toxicities
- On the basis of results from the ZUMA-5 trial, the CD19-directed chimeric antigen receptor T-cell therapy axicabtagene ciloleucel recently received FDA approval for patients with relapsed/refractory disease after 2 or more lines of systemic therapy for which type of cancer?**
  - Mantle cell lymphoma
  - Chronic lymphocytic leukemia
  - Follicular lymphoma
  - Hodgkin lymphoma
- The Phase II FIGHT trial is investigating modified FOLFOX6 with or without bezarituzumab for patients with previously untreated advanced gastric or gastroesophageal junction cancer. What is the target of bezarituzumab?**
  - HER2
  - FGFR2b
  - KRAS
  - EGFR/HER2 dual target
- Which of the following conditions was reported as an adverse event of special interest in the DESTINY-CRC01 trial of trastuzumab deruxtecan for patients with HER2-expressing metastatic colorectal cancer?**
  - New secondary cancer
  - Ocular toxicity
  - Interstitial lung disease
- Which of the following describes the mechanism of action of the novel agent mirvetuximab soravtansine?**
  - Anti-PD-1/PD-L1 antibody
  - Antibody-drug conjugate
  - PARP inhibitor
  - FGFR2 inhibitor
  - VEGF growth factor inhibitor
- Sotorasib recently received FDA approval for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with which of the following genetic alterations?**
  - EGFR exon 20 insertion mutation
  - MET exon 14 skipping mutation
  - KRAS G12C substitution mutation
  - HER2/HER3 overexpression
- Which of the following agents recently received FDA approval for patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations?**
  - Amivantamab
  - Osimertinib
  - Tiragolumab

ASCO Highlights and More: Investigators Review Recent Data Sets and Provide Perspectives on Current Oncology Care

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Which of the following agents received FDA approval, based on the results of the HER2CLIMB study, in combination with trastuzumab and capecitabine for patients with previously treated, advanced HER2-positive breast cancer (BC), including those with brain metastases?
- a. Tucatinib
  - b. Trastuzumab deruxtecan
  - c. T-DM1
  - d. Mirvetuximab soravtansine
  - e. Patritumab deruxtecan
10. The Phase III OlympiA trial is investigating the efficacy and safety of the PARP inhibitor olaparib for BC in patients with germline BRCA1/2 mutations and for high-risk HER2-negative early BC in which setting?
- a. In combination with chemotherapy as neoadjuvant therapy
  - b. As adjuvant therapy after (neo) adjuvant chemotherapy